EXEL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Exelixis Inc (EXEL) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 to invest. While the company has shown solid financial growth and has positive analyst sentiment, the lack of strong technical indicators, insider selling, and limited near-term catalysts suggest holding off on purchasing the stock right now.
The MACD is negative and expanding, RSI is neutral at 42.641, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 42.548, with resistance at 43.977 and support at 41.12. Overall, technical indicators suggest a lack of strong momentum in either direction.
Strong Q4 financial performance with a 74.84% YoY increase in net income and 83.33% YoY growth in EPS.
Positive analyst ratings with multiple price target increases, including H.C. Wainwright raising its target to $
Sustained growth in oncology product revenues.
Insider selling has increased significantly by 828.52% in the last month, signaling potential lack of confidence from insiders.
Revenue for Q4 missed estimates, causing a slight decline in stock price.
Limited high-impact catalysts in 2026, as noted by analysts, and concerns over patent life of key products.
In Q4 2025, revenue increased by 5.63% YoY to $598.66 million, net income surged by 74.84% YoY to $244.53 million, and EPS grew by 83.33% YoY to $0.88. However, gross margin slightly declined by 0.93% YoY to 95.58%. Overall, financial performance is solid, showcasing strong profitability and growth.
Analysts are generally positive on EXEL, with multiple price target increases. H.C. Wainwright has a Buy rating with a $54 target, while other firms like Stifel and Barclays have raised their targets to $44 but maintain Hold or Equal Weight ratings. However, Morgan Stanley and BofA have downgraded the stock due to valuation concerns and limited catalysts.
